Ken Murray

Ken Murray held an incredibly rigorous background in molecular biology, serving as a highly distinguished professor and the pioneering head of molecular biology at the University of Edinburgh. His deep, foundational academic research focused on recombinant DNA and viral genetics. This massive scientific expertise provided the precise intellectual and technical framework required to successfully engineer the world's first recombinant vaccine for hepatitis B.

Biogen is one of the foundational pillars of the global biotechnology industry, founded in 1978 in Geneva, Switzerland, by a syndicate of some of the most effective and decorated scientists in human history. The founding group included two future Nobel Laureates: Walter Gilbert (a molecular biologist at Harvard who won the Nobel Prize in Chemistry for developing a method to sequence DNA) and Phillip Sharp (a biologist at MIT who won the Nobel Prize in Medicine for his discovery of split genes). They were brought together by an effective venture capitalist named Kevin Kinsella and a seasoned pharmaceutical executive named Ray Schaefer. The founding of Biogen (which originally stood for 'Biotechnology Geneva') occurred precisely at the dawn of the recombinant DNA revolution. While its rival Genentech was focused on synthesizing human insulin, Biogen's founders were obsessed with interferon, a naturally occurring protein that scientists believed could be a miraculous cure for cancer and viral infections. In 1980, Charles Weissmann, one of Biogen's founding scientists, achieved a breakthrough by cloning leukocyte interferon alpha. This proved that a small biotech startup could outmaneuver the R&D budgets of legacy pharmaceutical giants. The company subsequently moved its headquarters to Cambridge, Massachusetts, anchoring what would become Kendall Square, the most densely concentrated biotechnology hub on Earth. While interferon ultimately proved to be a failure as a universal cancer cure, the deep, high-quality scientific rigor established by Gilbert, Sharp, and Weissmann provided the foundational DNA that allowed Biogen to eventually pivot and dominate the treatment of multiple sclerosis.